人福医药
(600079)
| 流通市值：319.44亿 | | | 总市值：337.87亿 |
| 流通股本：15.43亿 | | | 总股本：16.32亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,137,399,886.05 | 25,435,484,349.43 | 19,143,374,654.64 | 12,861,283,334.71 |
| 营业收入 | 6,137,399,886.05 | 25,435,484,349.43 | 19,143,374,654.64 | 12,861,283,334.71 |
| 二、营业总成本 | 5,336,905,257.79 | 22,665,868,260.22 | 16,644,223,107.45 | 11,126,432,608.62 |
| 营业成本 | 3,157,243,979.93 | 14,103,261,109.49 | 10,192,306,440.83 | 6,844,655,355.35 |
| 税金及附加 | 53,801,601.16 | 178,308,916.4 | 160,955,318.04 | 104,285,980.11 |
| 销售费用 | 1,164,947,366.72 | 4,630,565,520.92 | 3,477,070,885.85 | 2,380,822,325.92 |
| 管理费用 | 485,191,248.81 | 1,932,469,488.11 | 1,393,358,750.94 | 935,874,304.57 |
| 研发费用 | 408,787,039.15 | 1,470,559,384.57 | 1,093,259,846.85 | 705,834,992.85 |
| 财务费用 | 66,934,022.02 | 350,703,840.73 | 327,271,864.94 | 154,959,649.82 |
| 其中:利息费用 | 80,918,552.85 | 351,369,188.89 | 269,916,260.54 | 178,694,372.28 |
| 其中:利息收入 | 9,086,599.35 | 52,098,439.42 | 40,151,700.63 | 33,601,816.2 |
| 加:公允价值变动收益 | -847,377.55 | 112,716,765.01 | -7,258,698.89 | -5,660,932.78 |
| 加:投资收益 | 26,513,827.18 | 133,085,667.02 | 80,482,162.86 | 28,708,651.29 |
| 资产处置收益 | 1,840,394.68 | -4,472,024.18 | -3,113,228.19 | -532,848.97 |
| 资产减值损失(新) | 1,330,010.64 | -393,861,278.28 | -4,248,993.13 | -4,036,730.68 |
| 信用减值损失(新) | -15,983,130.09 | -283,184,107.26 | -48,798,603.11 | -30,068,997.03 |
| 其他收益 | 43,955,625.3 | 188,127,460.48 | 139,499,178.04 | 96,923,675.5 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 857,303,978.42 | 2,522,028,572 | 2,655,713,364.77 | 1,820,183,543.42 |
| 加:营业外收入 | 1,331,732.81 | 9,364,111.05 | 6,481,674.13 | 1,265,964.16 |
| 减:营业外支出 | 31,193,035.99 | 108,562,341.6 | 73,211,831.95 | 45,981,154.96 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 827,442,675.24 | 2,422,830,341.45 | 2,588,983,206.95 | 1,775,468,352.62 |
| 减:所得税费用 | 128,827,632.17 | 644,487,411.01 | 481,602,428.62 | 319,838,000.16 |
| 六、净利润 | 698,615,043.07 | 1,778,342,930.44 | 2,107,380,778.33 | 1,455,630,352.46 |
| 持续经营净利润 | 698,615,043.07 | 1,778,342,930.44 | 2,107,380,778.33 | 1,455,630,352.46 |
| 归属于母公司股东的净利润 | 540,345,459.39 | 1,329,744,984.33 | 1,589,694,392.14 | 1,111,094,974.15 |
| 少数股东损益 | 158,269,583.68 | 448,597,946.11 | 517,686,386.19 | 344,535,378.31 |
| (一)基本每股收益 | 0.33 | 0.82 | 0.98 | 0.68 |
| (二)稀释每股收益 | 0.33 | 0.82 | 0.97 | 0.68 |
| 八、其他综合收益 | -26,945,270.08 | 132,562,352.95 | 121,805,252.07 | -133,563,877.3 |
| 归属于母公司股东的其他综合收益 | -29,588,767.26 | 148,435,495.43 | 131,483,333.54 | -124,962,560.43 |
| 九、综合收益总额 | 671,669,772.99 | 1,910,905,283.39 | 2,229,186,030.4 | 1,322,066,475.16 |
| 归属于母公司股东的综合收益总额 | 510,756,692.13 | 1,478,180,479.76 | 1,721,177,725.68 | 986,132,413.72 |
| 归属于少数股东的综合收益总额 | 160,913,080.86 | 432,724,803.63 | 508,008,304.72 | 335,934,061.44 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-30 | 2024-07-27 |
| 审计意见(境内) | | 带强调事项段的无保留意见 | | |